Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.

All News

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms
BiotechnologyCompany Update

Moolec Science Enters Into Transformational Transaction Expanding Across Multiple Technology Platforms

April 21, 2025 7:00 AM

Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination").Subject to the terms and conditions of the BCA, which was...

Read more
Paradromics Announces Stephen Ryu, MD, as Chief Medical Officer
BiotechnologyCompany Update

Paradromics Announces Stephen Ryu, MD, as Chief Medical Officer

April 17, 2025 1:00 PM

Paradromics Inc., a neurotechnology company developing the highest data-rate brain-computer interface (BCI) platform, today announced the appointment of Dr. Stephen Ryu as Chief Medical Officer (CMO). Dr. Ryu, a board certified neurosurgeon, is the Chair of Neurosurgery at the Palo Alto Medical Foundation and holds adjunct professorships in Electrical Engineering and Neurosurgery at Stanford University. Dr. Ryu has been a key figure in the...

Read more
Holding in Company
BiotechnologyRegulatory

Holding in Company

April 17, 2025 8:45 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces that, on 16 April 2025, A&B (HK) Company Ltd (" A&B ") divested its entire shareholding of 3,559,893 ordinary shares representing approximately 3.40% of the Company's issued share capital.A&B (HK) Company Ltd, an investment and development company based in Hong Kong,...

Read more
Bora Biologics Unveils Cutting-Edge Innovations at Festival of Biologics 2025
BiotechnologyConferences

Bora Biologics Unveils Cutting-Edge Innovations at Festival of Biologics 2025

April 17, 2025 7:00 AM

Bora Biologics is set to showcase its innovative Allosteric Formulation Platform at the Festival of Biologics 2025, demonstrating advancements in biologics development. This year's conference is taking place at the San Diego Convention Center, April 23-24, 2025. Attendees are invited to visit Booth 632 to discover how Bora Biologics' pioneering approaches can enhance biologics development.Pawel Stanczak, PhD, Director of Process and Drug Product...

Read more
Aspira Women’s Health Inc. to Begin Trading April 17th On  OTC Under the Symbol
BiotechnologyCompany Update

Aspira Women’s Health Inc. to Begin Trading April 17th On OTC Under the Symbol "AWHL"

April 17, 2025 6:00 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that at beginning of trading on April 17, 2025, the Company expects that its Common Stock will begin trading under its new symbol "AWHL" on markets operated by the OTC Markets Group, Inc. This symbol replaces the prior symbol "AWH" under which the...

Read more
Aspira Women's Health Inc. Announces Receipt of Delisting Notification from Nasdaq
BiotechnologyCompany Update

Aspira Women's Health Inc. Announces Receipt of Delisting Notification from Nasdaq

April 16, 2025 4:00 PM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that on April 15, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq...

Read more
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
BiotechnologyCompany Update

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

April 16, 2025 8:30 AM

enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Tuesday, April 22, 2025 at 4:00 PM ET.As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's portfolio of novel...

Read more
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
BiotechnologyManagement Changes

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

April 15, 2025 9:00 AM

Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas Capital and Co-Founder of President Street Global, to its Board of Directors, increasing the size of the Board to seven Directors.This appointment strengthens Tharimmune's strategic leadership and will support the company's next phase of growth and...

Read more
Baylink Biosciences To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
BiotechnologyCompany Update

Baylink Biosciences To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

April 15, 2025 7:00 AM

Baylink Biosciences today announced that new preclinical data from its portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025, in Chicago, IL. These data provide insights into the potential of Baylink's innovative Antibody Drug Conjugate platform in treatment of cancers with high unmet medical need. Scientists at Baylink have invented a platform technology that enables the...

Read more
Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome
BiotechnologyRegulatory

Inside Information: Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome

April 15, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS)Key HighlightsTopline read-out from the Phase II BEXMAB trial confirms earlier positive findings in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome (HR MDS) patientsThe combination of bexmarilimab and azacitidine remains very well toleratedFull data has been...

Read more
PulpFixin Announces Strategic Distribution Partnership with Wildcat Laboratory Solutions  to Expand Sustainable Lab Products Across the UK And EU
BiotechnologyPartnerships

PulpFixin Announces Strategic Distribution Partnership with Wildcat Laboratory Solutions to Expand Sustainable Lab Products Across the UK And EU

April 14, 2025 12:00 PM

PulpFixin, an innovator of sustainable laboratory products, announced today a new distribution partnership with Wildcat Laboratory Solutions (www.wildcatls.com), a leading provider of lab equipment and solutions across the United Kingdom and European Union. This strategic collaboration marks a significant step forward in delivering eco-conscious, high-performance alternatives to single-use plastic products in biotech and pharmaceutical labs...

Read more
Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
BiotechnologyCompany Update

Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)

April 14, 2025 7:00 AM

Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a commercial stage biopharmaceutical company focused on using lipid technology to develop products to treat diseases with significant unmet medical needs, announced today a non-brokered private placement of preferred shares in the capital of Lobe Sciences' newly created subsidiary Cynaptec Pharmaceuticals, Inc. ("Cynaptec") for an initial gross proceeds of...

Read more
Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit
BiotechnologyCompany Update

Bionoid Pharma Inc. Announces Completion of 2024 Financial Audit

April 11, 2025 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its audited financial statements for the fiscal year ended December 31, 2024. The audit was conducted by Aloba Awomolo & Partners LLP, Chartered Professional Accountants, who were engaged earlier this year as Bionoid's external auditor."This marks an important milestone for Bionoid," said Wayne Cockburn, CEO of Bionoid Pharma. "Completing our...

Read more
Elizabeth Fraley, CEO of Kinder Ready, Launches a Summer Learning Initiative with Proven Strategies to Boost Early Mathematics for Young Learners
BiotechnologyCompany Update

Elizabeth Fraley, CEO of Kinder Ready, Launches a Summer Learning Initiative with Proven Strategies to Boost Early Mathematics for Young Learners

April 11, 2025 7:25 AM

Elizabeth Fraley Kinder Ready, is excited to announce a new Summer Learning Initiative designed to keep young learners academically engaged and confident during the break. As the CEO and founder of Kinder Ready Tutoring, Elizabeth Fraley brings her deep expertise in early childhood education to support students in retaining knowledge, building essential academic skills, and staying inspired to learn beyond the classroom.Under the direction of...

Read more
Kinder Ready's CEO Elizabeth Fraley, Announces an Expert Guide to Help Families Choose the Right Private School for Their Children
BiotechnologyCompany Update

Kinder Ready's CEO Elizabeth Fraley, Announces an Expert Guide to Help Families Choose the Right Private School for Their Children

April 11, 2025 7:00 AM

Kinder Ready Elizabeth Fraley announces an expert guide designed to help families navigate the overwhelming task of choosing a private school that aligns with their child's academic, emotional, and social development needs. Leveraging her extensive experience in early childhood education, she has developed a comprehensive resource to simplify decision-making for parents.Through personalized consultations and educational resources, Kinder Ready...

Read more
VoluMetrix Wins People’s Choice Award at American College of Cardiology NIH-NHLBI Company Showcase
BiotechnologyAwards

VoluMetrix Wins People’s Choice Award at American College of Cardiology NIH-NHLBI Company Showcase

April 10, 2025 9:00 AM

VoluMetrix, an innovative leader in non-invasive cardiovascular monitoring solutions, is proud to announce that it has been awarded the People's Choice Award at the ACC25-NHLBI Company Showcase, held during the American College of Cardiology's Annual Scientific Session in Chicago.The prestigious event, hosted on March 29 in the exhibit hall's Future Hub, featured presentations from four cutting-edge companies selected from a competitive pool of...

Read more
Xenetic Biosciences, Inc. Releases Virtual Investor
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

April 9, 2025 9:15 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing difficult to treat cancers, today announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment.As part of the segment, Dr. Bissonnette discussed key highlights from...

Read more
BRK Technology Driving Sustainability With Algae Biofuels
BiotechnologyEnvironmental, Social and Governance

BRK Technology Driving Sustainability With Algae Biofuels

April 9, 2025 9:00 AM

BRK Technology Co., Limited is excited to highlight how algae biofuels will play a critical role in helping companies meet their emission reduction targets in the years ahead. As businesses face increasing pressure to reduce their carbon footprints, algae biofuels offer a sustainable and scalable solution for achieving environmental goals while maintaining operational efficiency.Algae biofuels, derived from algae species cultivated in controlled...

Read more
Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
BiotechnologyCompany Update

Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements

April 9, 2025 7:30 AM

Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced it has engaged Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year ended December 31, 2024.This engagement underscores Bionoid's commitment to robust financial governance and transparency, aligning with its strategic initiatives to enhance market presence and shareholder value."We are pleased to welcome Aloba,...

Read more
Ondine Biomedical Inc. - Economic Study Suggests c.£200 Million UK Savings
BiotechnologyRegulatory

Ondine Biomedical Inc. - Economic Study Suggests c.£200 Million UK Savings

April 9, 2025 2:00 AM

Ondine Biomedical Inc. (LON:OBI) announces that a new health economic analysis by the York Health Economics Consortium (YHEC) has confirmed that using Steriwave® nasal decolonization prior to major surgery delivers substantial net cost savings. YHEC has demonstrated that for every £1 spent on Steriwave to prevent surgical site infections (SSI), the NHS can save an average of £1.49 to £2.38 across major surgical specialties. With £38 to £107 net...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?